Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas

Cancer

Volumn 116, Issue 20, 2010, Pages 4686-4695

  Zucali, Paolo A ^a   Petrini, Iacopo ^b   Lorenzi, Elena ^a   Merino, Maria ^b   Cao, Liang ^b   Di Tommaso, Luca ^a   Lee, Hye Seung ^b   Incarbone, Matteo ^a   Walter, Beatriz A ^b   Simonelli, Matteo ^a   Roncalli, Massimo ^a   Santoro, Armando ^a   Giaccone, Giuseppe ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Expression; Immunohistochemistry; Insulin like growth factor 1 receptor; Prognosis; Thymoma

Indexed keywords

PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; ONCOPROTEIN; SERINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE RELATED SURVIVAL; ENZYME PHOSPHORYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENT CANCER; RETROSPECTIVE STUDY; THYMOMA; THYMUS CANCER; TISSUE MICROARRAY; METABOLISM; MIDDLE AGED; MORTALITY; PHOSPHORYLATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, IGF TYPE 1; SERINE; THYMOMA; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 77957569631     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25367     Document Type: Article

References (40)

1. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105:546-551. (Pubitemid 36578561)
2. Takeda S, Miyoshi S, Akashi A, et al. Clinical spectrum of primary mediastinal tumors: a comparison of adult and pediatric populations at a single Japanese institution. J Surg Oncol. 2003;83:24-30. (Pubitemid 36528705)
3. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer. 2002;94:624-632. (Pubitemid 34132289)
4. Maggi G, Giaccone G, Donadio M, et al. Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer. 1986;58:765-776. (Pubitemid 16072083)
5. Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res. 2003;63:3708-3715. (Pubitemid 36793056)
6. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg. 2003;76:878-884; discussion 884-885. (Pubitemid 37100765)
7. Rajan A, Giaccone G. Treatment of advanced thymoma and thymic carcinoma. Curr Treat Options Oncol. 2008;9:277-287.
8. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, Connolly G, Debb G, Ramnath N. Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. Am J Clin Oncol. 2004;27:68-72. (Pubitemid 38176294)
9. Lucchi M, Mussi A, Ambrogi M, et al. Thymic carcinoma: a report of 13 cases. Eur J Surg Oncol. 2001;27:636-640. (Pubitemid 33062170)
10. Dufourny B, Alblas J, van Teeffelen HA, et al. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem. 1997;272:31163-31171. (Pubitemid 27527567)
11. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21:215-244. (Pubitemid 32275588)
12. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997;1332:F105-F126. (Pubitemid 27272620)
13. Blakesley VA, Stannard BS, Kalebic T, Helman LJ, LeRoith D. Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol. 1997;152:339-344. (Pubitemid 27102197)
14. Chu YW, Schmitz S, Choudhury B, et al. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood. 2008;112:2836-2846.
15. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 2008;8:915-928.
16. Bruchim I, Attias Z, Werner H. Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets. 2009;13:1179-1192.
17. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the antiinsulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Cancer Res. 2007;13:5834-5840. (Pubitemid 47583908)
18. McKian KP, Haluska P. Cixutumumab. Expert Opin Investig Drugs. 2009;18:1025-1033.
19. Masaoka A, Yamakawa Y, Niwa H, et al. Thymectomy and malignancy. Eur J Cardiothorac Surg. 1994;8:251-253.
20. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol. 2004;22:1501-1509. (Pubitemid 41103633)
21. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008;68:8039-8048.
22. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995;55:237-241.
23. Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma: a clinicopathologic study based on the new World Health Organization classification. J Thorac Cardiovasc Surg. 2003;126:1134-1140. (Pubitemid 37305702)
24. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer. 2002;95:420-429. (Pubitemid 34787609)
25. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
26. Rocha RL, Hilsenbeck SG, Jackson JG, et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997;3:103-109. (Pubitemid 27079451)
27. Ludovini V, Bellezza G, Pistola L, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 2009;20:842-849.
28. Brodt P, Samani A, Navab R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol. 2000;60:1101-1107.
29. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol. 2001;54:133-137. (Pubitemid 32539602)
30. Zhou R, Zettl A, Strobel P, et al. Thymic epithelial tumors can develop along 2 different pathogenetic pathways. Am J Pathol. 2001;159:1853-1860. (Pubitemid 33062527)
31. Girard N, Mornex F, Van Houtte P, Cordier JF, van Schil P. Thymoma: a focus on current therapeutic management. J Thorac Oncol. 2009;4:119-126.
32. Giaccone G, Rajan A, Ruijter R, Smit EF, van Groeningen C, Hogedoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thoracic Oncol. 2009;4:1270-1273.
33. Salter J, Lewis D, Yiannoutsos C, Loehrer PJ, Risley L, Chiorean EG. Imatinib for the treatment of thymic carcinoma [abstract]. J Clin Oncol. 2008;26S. Abstract 8116.
34. Kurup A, Burns M, Dropcho S, Pao S, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies [abstract]. J Clin Oncol. 2005;23(16S). Abstract 7968.
35. Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A. Response of thymoma to cetuximab. Lancet Oncol. 2007;8:449-450. (Pubitemid 46621774)
36. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol. 2004;202:375-381. (Pubitemid 38325248)
37. Meister M, Schirmacher P, Dienemann H, et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett. 2007;248:186-191. (Pubitemid 46330550)
38. Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol. 2006;36:351-356. (Pubitemid 44043923)
39. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127-137. (Pubitemid 36588961)
40. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002;62:200-207. (Pubitemid 34074005)